|
|
| (21 intermediate revisions by 5 users not shown) |
| Line 1: |
Line 1: |
| {{SI}} | | __NOTOC__ |
| {{WikiDoc Cardiology Network Infobox}} | | {{Stent thrombosis}} |
| | {{CMG}} ; '''Associate Editors-In-Chief:''' Smita Kohli, M.D.; [[ William J. Gibson]]; [[Varun Kumar]], M.B.B.S.; [[Lakshmi Gopalakrishnan]], M.B.B.S. |
|
| |
|
| '''Editors-In-Chief:''' Allen Jeremias, M.D., SUNY; Don Cutlip, M.D. Beth Israel Deaconess Medical Center, Harvard
| | ==[[Stent thrombosis introduction|Introduction]]== |
|
| |
|
| '''Associate Editors-In-Chief:''' Priyantha Ranaweera, M.D.; William J. Gibson, MIT
| | ==[[Stent thrombosis definition|Definition]]== |
| | ==Epidemiology and Demographics== |
| | [[Stent thrombosis incidence in bare metal stents|Relation to Bare Metal Stents]] | [[Stent thrombosis Relation to drug eluting stents|Relation to Drug Eluting Stents]] | [[Stent thrombosis with antithrombotics|Relation to Antiplatelet Medications]] |
|
| |
|
| {{Editor Help}}
| | ==[[Stent thrombosis pathophysiology|Pathophysiology]]== |
| | ==[[Stent thrombosis risk factors|Risk Factors]]== |
|
| |
|
| ==[[Introduction]]== | | ==[[Stent thrombosis relationship to discontinuation of antiplatelet therapy|Relationship to Discontinuation of Antiplatelet Therapy]]== |
| ==[[Definitions - coronary stent thombosis (ST)]]==
| |
| ==[[Mechanism and pathophysiology of coronary stent thrombosis (ST)]]==
| |
| ==[[Incidence of coronary stent thrombosis (ST) in bare metal stents (BMS)]]==
| |
| ==[[Incidence of coronary stent thrombosis (ST) in drug eluting stents (DES)]]==
| |
| ==[[Incidence of drug eluting stent thrombosis (ST) in relation to antiplatelet medication use]]==
| |
| ==[[Future Directions]]==
| |
| At the request of the FDA, four major drug companies and four major device companies are jointly investigating the best strategy to avoid clot formation in patients that have received stents. The $100 million, four-year study of 20,000 patients will specifically examine whether patients should remain on blood-thinners for 1 or 2.5+ years after PCI. Companies involved include: Bristol-Myers Squibb, Sanofi-Aventis, Eli Lilly, Daiichi Sankyo, Abbott, Medtronic, Boston Scientific, and Johnson & Johnson. This study was presented at TCT 2008 by Dr. Laura Mauri, a co-principal investigator of the study.<ref>http://online.wsj.com/article/SB122411707038238773.html?mod=rss_whats_news_us_busines</ref>
| |
|
| |
|
| ==References== | | ==[[Stent thrombosis treatment|Treatment]]== |
| {{Reflist|2}}
| |
|
| |
|
| ==Additional Resources== | | ==[[Stent thrombosis complications|Complications]]== |
| {{refbegin|2}}
| |
| # Singh M Et al. Influence of coronary thrombus on outcome of percutaneous coronary angioplasty in the current eta (the mayo clinc experince). Am J Cardiol 2001;88:1091-6
| |
| # White CJ et al. Coronary thrombi increase PTCA risk. Angioscopy as a clinicla tool. Circulation 1996;93:253-8
| |
| # G Sianos, et al. Angiographic stent thrombosis after routine use of drug eluting stents in ST -Segement elevation myocardial infarction, the importance of thrombus burden. JACC, Vol 50, No 7, 2007
| |
| # C. Spaulding, et al. Sirolimus-Eluting versus Uncoated Stents in acute myocardial infarction, N Engl J Med 2006;355:1093-104.
| |
| # Menichelli M . Sirolimus stent versus bare stent in acute myocardial infarction trail, Presented at European Percutaneou Cororanry Revascularizaton 2006.
| |
| {{refend}}
| |
| | |
| ==External links==
| |
| * [http://www.themdtv.org The MD TV: Comments on Hot Topics, State of the Art Presentations in Cardiovascular Medicine, Expert Reviews on Cardiovascular Research]
| |
| * [http://www.clinicaltrialresults.org Clinical Trial Results: An up to dated resource of Cardiovascular Research]
| |
| | |
| | |
| {{Electrocardiography}}
| |
| {{Circulatory system pathology}}
| |
| {{SIB}}
| |
|
| |
|
| | ==[[Stent thrombosis prevention|Prevention]]== |
|
| |
|
| [[Category:Cardiology]] | | [[Category:Cardiology]] |